Cargando…
Oral IRAK-4 Inhibitor CA-4948 Is Blood-Brain Barrier Penetrant and Has Single-Agent Activity against CNS Lymphoma and Melanoma Brain Metastases
PURPOSE: An ongoing challenge in cancer is the management of primary and metastatic brain malignancies. This is partly due to restrictions of the blood-brain barrier and their unique microenvironment. These challenges are most evident in cancers such as lymphoma and melanoma, which are typically res...
Autores principales: | Von Roemeling, Christina A., Doonan, Bently P., Klippel, Kelena, Schultz, Daniel, Hoang-Minh, Lan, Trivedi, Vrunda, Li, Chenglong, Russell, Rylynn A., Kanumuri, Raju S., Sharma, Abhisheak, Tun, Han W., Mitchell, Duane A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10150246/ https://www.ncbi.nlm.nih.gov/pubmed/36749885 http://dx.doi.org/10.1158/1078-0432.CCR-22-1682 |
Ejemplares similares
-
P1298: THE IRAK-4 INHIBITOR EMAVUSERTIB (CA-4948) FOR THE TREATMENT OF PRIMARY CNS LYMPHOMA
por: Von Roemeling, C., et al.
Publicado: (2022) -
CXCL9 recombinant adeno-associated virus (AAV) virotherapy sensitizes glioblastoma (GBM) to anti-PD-1 immune checkpoint blockade
por: von Roemeling, Christina, et al.
Publicado: (2023) -
S129: TAKEAIM LEUKEMIA- A PHASE 1/2A STUDY OF THE IRAK4 INHIBITOR EMAVUSERTIB (CA-4948) AS MONOTHERAPY OR IN COMBINATION WITH AZACITIDINE OR VENETOCLAX IN RELAPSED/REFRACTORY AML OR MDS
por: Garcia-Manero, G., et al.
Publicado: (2022) -
IRAK-4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignancies
por: Parrondo, Ricardo D., et al.
Publicado: (2023) -
ATM-Inhibitor AZD1390 Is a Radiosensitizer for Breast Cancer CNS Metastasis
por: Tew, Ben Yi, et al.
Publicado: (2023)